| 纯度 | > 90 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD58 |
| Uniprot No | P19256 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 29-215aa |
| 氨基酸序列 | FSQQIYGVVY GNVTFHVPSN VPLKEVLWKK QKDKVAELEN SEFRAFSSFK NRVYLDTVSG SLTIYNLTSS DEDEYEMESP NITDTMKFFL YVLESLPSPT LTCALTNGSI EVQCMIPEHY NSHRGLIMYS WDCPMEQCKR NSTSIYFKME NDLPQKIQCT LSNPLFNTTS SIILTTCIPS SGHSRHR |
| 预测分子量 | 50 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CD58重组蛋白的3篇参考文献的简要列举(注：以下内容为示例性概括，实际文献需根据具体研究检索)：
1. **文献名称**：*CD58/LFA-3 acts as a costimulatory molecule in CAR-T cell therapy*
**作者**：Koyama S, et al.
**摘要**：研究探讨了CD58重组蛋白作为共刺激分子在CAR-T细胞治疗中的作用，发现其通过增强T细胞与靶细胞间的相互作用，显著提高了抗肿瘤活性。
2. **文献名称**：*Recombinant CD58 protein enhances dendritic cell-mediated T cell activation*
**作者**：Zhang Y, et al.
**摘要**：该文献报道了利用昆虫细胞表达系统制备的CD58重组蛋白，可有效促进树突状细胞对T细胞的活化能力，为疫苗佐剂开发提供了新思路。
3. **文献名称**：*Structural and functional characterization of human CD58 recombinant protein*
**作者**：Smith J, et al.
**摘要**：通过X射线晶体学解析了CD58重组蛋白的结构，并验证其与CD2受体的特异性结合，阐明了其在免疫突触形成中的分子机制。
如需具体文献，建议通过PubMed或Google Scholar以“CD58 recombinant protein”为关键词检索近年研究。
CD58 recombinant protein, also known as recombinant LFA-3 (lymphocyte function-associated antigen 3), is a genetically engineered protein derived from the human CD58 antigen. CD58 is a cell surface glycoprotein belonging to the immunoglobulin superfamily, primarily expressed on antigen-presenting cells (APCs), endothelial cells, and epithelial cells. It functions as a ligand for CD2. a receptor on T cells and natural killer (NK) cells, and plays a critical role in mediating cell-cell adhesion and immune synapse formation during T cell activation. This interaction enhances T cell receptor signaling, promotes cytotoxic responses, and regulates immune tolerance.
The recombinant form of CD58 is typically produced in mammalian expression systems (e.g., CHO or HEK293 cells) to ensure proper post-translational modifications. It retains the extracellular domain of CD58. which contains two Ig-like domains essential for binding to CD2. Researchers often utilize CD58 recombinant protein in soluble or immobilized formats to study T cell-APC interactions, develop immunotherapy strategies, or modulate immune responses in vitro. Its applications extend to autoimmune disease research, cancer immunotherapy (e.g., enhancing chimeric antigen receptor T cell efficacy), and infectious disease models where T cell activation is pivotal.
In drug development, CD58-CD2 signaling is explored as a therapeutic target. Inhibitors may suppress aberrant immune activation in autoimmune disorders, while agonists could boost antitumor immunity. Additionally, CD58 recombinant protein serves as a critical reagent in vaccine research to optimize antigen presentation. Its standardized production ensures consistency for functional assays, antibody development, and mechanistic studies, bridging basic immunology with translational biomedical applications.
×
